Antibody drug conjugates (ADCs)
This learning journey provides an introduction to ADCs, focusing on their mechanism, design, synthesis, and pharmacokinetics. It also explores associated safety and regulatory considerations.
Table of Contents
- What is an ADC?
- The modality and heterogeneity of ADCs and the opportunities they present
- ADC design and technology
- Important considerations in ADC design
- ADC composition, metabolism and optimisation
- ADC synthesis and stability
- ADC pharmacokinetics
- ADC safety and regulatory considerations
- Example of an ADC targeting HER2
1. What is an ADC?
By Dr. Veysel Kayser – The University of Sydney, Australia
An excerpt from Developing therapeutic monoclonal antibodies (mAbs) and antibody-based products 1
2. The modality and heterogeneity of ADCs and the opportunities they present
By Dr. Dhaval K. Shah – University at Buffalo, USA
An excerpt from Modeling of antibody-drug conjugate pharmacokinetics
3. ADC design and technology
By Prof. L. Nathan Tumey – Binghamton University, USA
An excerpt from Current challenges in the design of antibody-drug conjugates
4. Important considerations in ADC design
By Prof. Nishitha M. Reddy – Vanderbilt University Medical Center, USA
An excerpt from Novel treatment options in lymphoma and leukemia 1
5. ADC composition, metabolism and optimisation
By Dr. Hans-Georg Lerchen – Bayer AG, Germany
An excerpt from Development of antibody prodrug conjugates activated by legumain
6. ADC synthesis and stability
By Dr. Hans-Georg Lerchen – Bayer AG, Germany
An excerpt from Development of antibody prodrug conjugates activated by legumain
7. ADC pharmacokinetics
By Dr. Dhaval K. Shah – University at Buffalo, USA
An excerpt from Modeling of antibody-drug conjugate pharmacokinetics
8. ADC safety and regulatory considerations
By Dr. Krishna Allamneni – Concarlo Therapeutics, USA
An excerpt from Toxicity testing of oncology drugs: unraveling the last 15 years of progress
9. Example of an ADC targeting HER2
By Prof. Michael Wendt – Purdue University, USA
An excerpt from Receptor tyrosine kinase signaling and targeted therapies